Chlamydia Market to Reach $4.85B by 2030 with Steady Growth

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Chlamydia Market Progress Between 2026 And 2030?

The chlamydia market size has witnessed significant expansion in recent years. It is anticipated to expand from $3.23 billion in 2025 to $3.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The increase observed in the past period is largely due to the growing occurrence of sexually transmitted infections, the widening scope of public health screening efforts, better accessibility to diagnostic laboratories, heightened awareness regarding reproductive health, and the widespread availability of antibiotic treatment options.

The chlamydia market size is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $4.86 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This expansion during the projection period is driven by factors such as increasing demand for point-of-care diagnostics, a heightened focus on preventive sexual healthcare, the expansion of digital health screening platforms, growing investments in diagnostic innovation, and increasing government-led sti control programs. Key trends anticipated during the forecast period encompass the increasing adoption of rapid chlamydia testing methods, the rising use of naat-based diagnostic techniques, a growing focus on early sti screening programs, the expansion of home-based testing solutions, and enhanced awareness of asymptomatic infections.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

Which Key Factors Are Driving The Chlamydia Market Growth?

The rising occurrence of sexually transmitted diseases is anticipated to drive expansion in the chlamydia market in the future. Sexually transmitted diseases, or STDs, are infections communicated via sexual interaction, encompassing conditions such as chlamydia, gonorrhea, and HIV. This increase in STDs stems from several factors, including reduced condom usage, insufficient public awareness, restricted availability of healthcare services, and the widespread use of dating applications that can lead to a greater number of sexual partners. Treating chlamydia plays a crucial role in curbing the spread of STDs by eradicating the infection, averting complications, and decreasing the chance of transmitting it to others. As an illustration, in October 2025, data from the Minority HIV/AIDS Fund (MHAF), an US-based government agency, indicated that an estimated 39.9 million individuals globally were living with HIV in 2023, comprising 38.6 million adults and 1.4 million children, compared to previous years. Consequently, the expanding prevalence of sexually transmitted diseases is fueling the growth of the chlamydia market.

Which Segments Define The Chlamydia Market Segment Structure?

The chlamydia market covered in this report is segmented –

1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture

2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP)

3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection

4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot

5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)

Which Trends Are Guiding The Direction Of The Chlamydia Market?

Leading companies in the chlamydia market are concentrating on developing innovative approaches, such as the expansion of point-of-care molecular diagnostics, to enable faster, more accurate onsite detection and improve timely patient outcomes. Point-of-care molecular diagnostics expansion refers to the broader adoption of rapid, onsite molecular tests that permit immediate identification of infections like chlamydia without reliance on centralized laboratories. For instance, in January 2025, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, secured FDA 510(k) clearance and a CLIA waiver for its cobas liat molecular tests, which are designed for diagnosing sexually transmitted infections (STIs) directly at the point of care. These tests incorporate multiplex assay panels that can detect and differentiate multiple STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample, with results available in 20 minutes or less.

Who Are The Established Players Within The Chlamydia Market?

Major companies operating in the chlamydia market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc, Quidel Corporation, Bio-Rad Laboratories Inc, Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co Ltd, MedMira Inc, GenMark Diagnostics Inc, ACON Laboratories Inc, Biocartis Group NV, Inova Diagnostics Inc, Trinity Biotech Plc, Seegene Inc, Qiagen NV, Binx Health Inc, Chembio Diagnostics Inc, Visby Medical Inc.

Get The Full Chlamydia Market Report:

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

Which Region Leads The Chlamydia Market In Overall Market Size?

North America was the largest region in the chlamydia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Chlamydia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

Browse Through More Reports Similar to the Global Chlamydia Market 2026, By The Business Research Company

Sexually Transmitted Infections Stis Market Report 2026

https://www.thebusinessresearchcompany.com/report/sexually-transmitted-infections-stis-global-market-report

Chlamydia Infection Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report

Chlamydia Infection Diagnostics And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/chlamydia-infection-diagnostics-and-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795